David Miller, MD

home / authors / david-miller-md
  • Obstetrics and Gynecology - Gyn Oncology
  • Gynecologic Cancers
  • Surgical Treatment for Gynecologic Cancer

Articles

Long-term Follow-up of Selinexor Maintenance for Patients With TP53wt Advanced or Recurrent Endometrial Cancer: A Prespecified Subgroup Analysis From the Phase 3 ENGOT-EN5/GOG-3055/SIENDO Study

Long-term Follow-up of Selinexor Maintenance for Patients With TP53wt Advanced or Recurrent Endometrial Cancer: A Prespecified Subgroup Analysis From the Phase 3 ENGOT-EN5/GOG-3055/SIENDO Study

David Miller, MD
Published: August 6th 2024 | Updated: August 19th 2024

David Miller, MD, reviews a plenary presentation (originally presented at the ASCO 2024 Annual Meeting by Vikky Makker, MD) on the long-term follow-up of the ENGOT-EN5/GOG-3055/SIENDO trial, focusing on selinexor maintenance for patients with TP53 wild-type advanced or recurrent endometrial cancer.

Read More

David Miller, MD, professor, chief, Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Amy and Vernon R. Faulconer Distinguished Chair in Gynecologic Oncology, University of Texas (UT) Southwestern Medical School; medical director, UT Southwestern Harold C. Simmons Cancer Center

Miller Discusses the Use of Selinexor in TP53 Wild-Type Advanced Endometrial Cancer

David Miller, MD
July 25th 2024

Dr Miller discusses findings from the SIENDO trial of selinexor maintenance therapy in patients with TP53 wild-type advanced endometrial cancer.

Read More

Latest Updated Articles

Brigatinib in NF2-Related Schwannomatosis with Progressive Tumors
Published: August 22nd 2024 | Updated: August 29th 2024
Brigatinib in NF2-Related Schwannomatosis with Progressive Tumors
Long-term Follow-up of Selinexor Maintenance for Patients With TP53wt Advanced or Recurrent Endometrial Cancer: A Prespecified Subgroup Analysis From the Phase 3 ENGOT-EN5/GOG-3055/SIENDO Study
Published: August 6th 2024 | Updated: August 19th 2024
Long-term Follow-up of Selinexor Maintenance for Patients With TP53wt Advanced or Recurrent Endometrial Cancer: A Prespecified Subgroup Analysis From the Phase 3 ENGOT-EN5/GOG-3055/SIENDO Study
Sarwish Rafiq, PhD
Published: July 9th 2024 | Updated: July 10th 2024
Dr Rafiq on Novel Strategies for CAR T-Cell Engineering in Solid Tumors
Jens Hoeppner, FAChirg, FACS, MD
Published: June 2nd 2024 | Updated: June 3rd 2024
Perioperative Chemotherapy Prolongs OS vs Neoadjuvant Chemoradiation in Esophageal Cancer
OncLive’s August Roundup of Key FDA Approvals in Oncology
Published: September 4th 2024 | Updated: September 8th 2024
OncLive’s August Roundup of Key FDA Approvals in Oncology
Paula Rodriguez-Otero, MD, PhD
Published: June 4th 2024 | Updated: September 8th 2024
D-VRd Boosts MRD-Negativity Rates in Newly Diagnosed, Transplant-Eligible Multiple Myeloma